Induction of icam-1 hla-dr molecules by ifn-gamma and oncogene expression in human bladder cancer cell lines

Urologia Internationalis

Volumn 59, Issue 2, 1997, Pages 72-80

  Park, Dong Soo ^a   Park, Jeon Han ^a   Lee, Jung Lim ^a   Lee, Jae Myun ^a   Kim, Yeon Hyang ^a   Lee, Jin Moo ^a   Kim, Se Jong ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Bladder cancer cell lines; c Ha ras; c myc; HLA DR; ICAM 1; IFN

Indexed keywords

GAMMA INTERFERON; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; NORTHERN BLOTTING; ONCOGENE; ONCOGENE C H RAS; ONCOGENE C MYC; POINT MUTATION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR GROWTH;

EID: 0030731703     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000283027     Document Type: Article

References (36)

1. Fearon ER, Vogelstein B: A genomic model for colorectal tumorigcnesis, Cell 1990:61:759-767.
2. Garrido F, Cabrera T, Concha A, Glcw S, Ruiz-Cabello F, Stem PL: Natural history of HLA expression during tumor development, Immunol Today 1993:14:491-499.
3. Catalona WJ: Urothelial tumors of the urinary tract: in Walsh PC, Retik AB, Stamey TA, Vaughan EDV Jr (eds): Campbell’s Urology, ed 6, Philadelphia, Saunders, 1992, pp 1094-1158.
4. van den Eynde B, Hainaut P, Herin M, Knuth A, Lemoinc C, Weynants P, van der Bruggen P, Fauchet R, Boon T: Presence on a human melanoma of multiple antigens recognized by autologous CTL, Int J Cancer 1989:44:634-640.
5. Matsushita K, Takenouchi T, Kobavashi S, Hayashi H, Okuyama K, Ochiai T, Mikata A, Isono K: HLA-DR antigen expression on colorectal carcinomas: Influence of expression by IFN-y in situ and its association with tumour progression, Br J Cancer 1996:73:644-648.
6. Gasti G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, Bander NH: Major histocompatibility complex class 1 and class II expression in renal cell carcinoma and modulation by interferon gamma, J Urol 1996:155: 361-367.
7. Elliott BE, Carlow DA, Rodricks AM, Wade A: Perspectives on the role of MFIC antigens in normal and malignant cell development, Adv Cancer Res 1989:53:181-245.
8. Trinchicri G, Perussia B: Immune interferon: A pleiotrophic lymphokine with multiple effects, Immunol Today 1985:6:131-136.
9. Maio M, Gulwani B, Langer JA, Kerbel RS, Duigou GJ, Fisher PB, Fcrrone S: Modulation by interferons on HLA antigen, high-molecu-lar-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential, Cancer Res 1989:49:2980-2987.
10. Viola MV, Fromowitz F, Oravez S, Deb S, Schlom J: ras oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma, J Exp Med 1985:161: 1213-1218.
11. Dunn TL, Seymour GJ, Gardiner RAA, Strutton GM, Lavin MF: Immunocytochemical demonstration of p21 ra.s in normal and transitional cell carcinoma urothelium, J Pathol 1988 156:59-65.
12. Masters JR, Vesscy SG, Munn CF, Evan GI, Watson JV: c-myc oncoprotein levels in bladder cancer, Urol Res 1988;16:341-344.
13. Moriyama N, Umeda T, Akaza H, Taniguchi J, Kitamura T, Murakami T, Kawabe K, Aso Y: Expression of ras p21 oncogene product on human bladder tumors, Urol Int 1989:44:260-263.
14. Kotake T, Saiki S, Kinouchi T, Shiku H, Na-kayama E: Detection of the cm vegene product in urinary bladder cancer, Jpn J Cancer Res 1990;81:1198-1201.
15. Miao TJ, Wang Z, Sang N: Correlation between the expression of the p21 ras oncogene product and the biological behavior of bladder tumors, Eur Urol 1991:20:307-310.
16. Kubota Y, Yao M, Noguchi S, Ishibashi Y, Shuin T: Study of c-niyc gene transfected T-24 human bladder cancer cells, Jpn J Urol 1991; 82:593-599.
17. Knowles MA, Williamson M: Mutation of liras is infequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing, Cancer Res 1993:53:133-139.
18. Rigby CC, Franks LM: A human tissue culture cell line from a transitional cell tumour of the urinary bladder: Growth, chromosome pattern and ultrastructurc, Br J Cancer 1970:24:746-754.
19. Bubenik J, Baresova M, Viklickv V, Jakoub-kova J, Sainerova H, Donner J: Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen, Int J Cancer 1973:11:765-773.
20. O’Toole C, Price ZH, Ohnuki Y, Unsgaard B: Ultrastructure, karyology and immunology of a cell line originated from a human transitionalcell carcinoma, Br J Cancer 1978:38:64-76.
21. Nayak SK, O'Toole C, Price ZH: A cell line from an anaplastic transitional cell carcinoma of human urinary bladder, Br J Cancer 1977: 35:142-151.
22. Makgoba MW, Sanders ME, Ginther Luce GE, Dustin ML, Springer TA, Clark EA, Mannoni P, Shaw S: ICAM-I a ligand for LFA-l-depen-dcnt adhesion of B, T, and myeloid cells, Nature 1988:331:86-88.
23. Hansen GS, Rubin B, Sorensen SF, Svejgaard A: Importance of HLA-D antigens for the cooperation between human monocytes and T lymphocytes, Eur J Immunol 1978:8:520-525.
24. Kim SJ, Kim NS, Lee JL: Effect of cytokines on the expression of cell adhesion molecule and on the adhesion of melanoma cells to endothelial cells, J Korean Med Sci 1993:8:41-52.
25. Wake CT, Long EO, Strubin M, Gross N, Accolla R, Carrel S, Mach B: Isolation of cDNA clones encoding HLA-DR alpha chains, Proc Natl Acad Sci USA 1982:79:6979-6983.
26. Gustafsson K, Wiman K, Larhammar D, Rask L, Peterson PA: Signal sequences distinguish class II histocompatibility antigenal chains of different loci, Scand J Immunol 1984:19:91-97.
27. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Gocddcl DV: Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue, Nature 1983:302:33-37.
28. Alitalo K, Bishop JM, Smith DH, Chen EY, Colby WW, Levinson AD: Nucleotide sequence of the v-myc oncogene of avian retrovirus MC29, Proc Natl Acad Sci USA 1983:80: 100-104.
29. Sambrook J, Fitsch EF, Maniatis T: RNA analysis; in Ford N (ed): Molecular Cloning, ed 2, New York, Cold Spring Harbor Laboratory Press, 1989, pp 737-752.
30. Zoll GJ, Melchers WJ, Kopecka H, Jambroes G, van der Poel HJ, Galama JM: General primer-mediated polymerase chain reaction for detection of enteroviruses: Application for diagnostic routine and persistent infections, J Gen Microbiol 1992:30:160-165.
31. Sanger F, Nicklen S, Coulson A: DNA sequencing with chain-terminating inhibitors, Proc Natl Acad Sci USA 1977;74:5463-5467.
32. Johnson JP, Stade BG, Holzman B, Schwable W, Riethmuller G: De novo expression of in-tercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis, Proc Natl Acad Sci USA 1989:86:641-644.
33. Daar AS, Fugglc SV, Fabre J W, Ting A, Morris PJ: The detailed distribution of MHC class II antigens in normal human organs, Transplantation 1984:38:293-298.
34. Hawkyard S, James K, Prescott S, Jackson AM, Ritchie AW, Smyth JF, Chisholm GD: The effects of recombinant human intcrferon-gam-nta on a panel of human bladder cancer cell lines, J Urol 1991;145:1078-1081.
35. Ottescn SS, Ahrcnkiel V, Kieler J: Recombinant human interferon gamma exerts an antiproliferative effect and modulates the expression of human leukocyte antigens ABC and DR in human urothelial cell lines, Cancer Immu-nother 1990:31:93-98.
36. Gariglio M, Gribaudo G, Franco A, Pierolti M, Cavallo G, Landolfo S: Inhibition of interfer-on-y antiviral and antiproliferative activities by ras oncogene expression, J Natl Cancer Inst 1989:81:1014-1020.